Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Therapeutics > Hepatitis > Flashcards

Hepatitis Flashcards

1
Q

Hep B Serologic Markers :

What is it and what does it tell you about the DNA virus ?

  1. HbsAg
  2. Anti -HBs
  3. HBeAg
    4.Anti - HBe
  4. HBcAg
  5. Anti-HBc
A
  1. Hep B surface antigen –> present in acute and chronic infection ; carriers
  2. Antibody to HBsAg –> Past infection and immunity to HBV
  3. Hepatitis Be antigen –> Indicates active viral replication
  4. Anti body to HBeAg –>Seroconversion
  5. Hep B core antigen –> present in nucleus
  6. ANtibody to HBcAg –> Indicates prior exposure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

For the following results, interpret them and state management and if you’d vaccinate

  1. HBsAg +, Anti-HBc +, Anti HBs neg
  2. HBsAg -, Anti-HBc +, Anti HBs pos
  3. HBsAg -, Anti-HBc +, Anti HBs neg
  4. HBsAg -, Anti-HBc -, Anti HBs pos
  5. HBsAg -, Anti-HBc -, Anti HBs neg
A
  1. Chronic Hep B . additional testing and management needed . no vaccination
  2. Past HBV infection that’s resolved. NO further management unless immunocomp or undergoing chemo or immunosupp therapy . No vax
  3. Past HBV infection , resolved or false positive. HBV DNA testing if immunocomp pt. YES vaccinate if not from area of intermediate or high endemicity
  4. Immune! No further testing. Don’t vax
  5. Uninfected and not immune. No further testing. Yes vaccinate.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hep B Clinical Features

  1. What are the extrahepatic manifestations? (3)
  2. Acute __ failure or fulminant ___
    - onset of ___ within 8 weeks of sx’s
    -poor prognosis
    -Supportive care and ___
A
  1. Arthralgias, rash , glomerulonephritis
  2. liver, hepatic failure
    - hepatic encephalopathy
    - liver transplant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Approved Therapies for HBV (3) for exam . Dosing + Main AE”s

  1. Entecavir (Baraclude)
  2. Tenofovir Disoproxil (Viread)
  3. Tenofovir Alafenamide (Vemlidy)
A
  1. 0.5 or 1 mg PO daily . Lactic acidosis
  2. 300 mg PO daily . Nephropathy, fanconic syndrome, osteomalacia, lactic acidosis
  3. 25 mg PO daily. Lactic acidosis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Entecavir (Baraclude)
-More potent than __ and ___ in vitro
-Slower rate of ___
-Dosing?
-In lamivudine resistance, the drug should be ___ when switching to entecavir
-When should you use a higher dose of entecavir?
-What are the common AE’s ? (4)
-What are the serious but rare AE’s?

A
  1. lamivudine, adefovir
  2. resistance
  3. 0.5 mg daily
  4. discontinued
  5. lamivudine resistant/refractory patients –> 1mg po daily
  6. HA, fatigue, nausea, dizziness
  7. Lactic acidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Tenofovir Disoproxil (Viread)

  1. It’s the ___ of ADEFOVIR, but its more __ and less ___
  2. Has low ___
  3. Dosing?
  4. Common ae’s? (4)
  5. Rare AE’s? (4)
A
  1. nucleotide analogue . potent, nephrotoxic
  2. resistance rates
  3. 300 mg PO once daily
  4. HA, nasopharyngitis, nausea, fatigue
  5. rena insufficiency, fanconi syndrome, osteomalacia, decr bone density
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Tenofovir Alafenamide (Vemlidy)

  1. It’s the prodrug of?
  2. This drug is more stable in ___ than viread . Vemlidy is able to establish ___ in target cells at ____ than viread
  3. Vemlidy has a lesser effect on ?
A
  1. tenofovir DF (viread)
  2. plasma/tissues. higher levels of TFV-disphos , lower doses
  3. proximal renal tubule
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tenofovir Alafenamide (Vemlidy)

  1. Dosing?
  2. AE’s common (4)
  3. Serious but rare AE’s ? (1)
  4. This drug is also a component of which drug used for HIV?
A
  1. 25 mg PO once daily WITH FOOD
  2. HA, nasophryngitis, nausea, fatigue
  3. Lactic acidosis but has lower incidence of renal and bone effects!
  4. Biktarvy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  1. What are some pros about Entecavir?

2.Pros of Viread? Cons?

  1. Pros of Vemlidy? Cons?
A
  1. It’s oral, well tolerated, high potency and low resistance
  2. Oral, well tolerated, high pot, low resist. Renal and bone considerations
  3. PO, well tolerated, high pot, low resistance. NOT in pt’s with Clcr < 15 mL/min or in dialysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HBV reactivation in pt’s receiving immunosuppression

  1. Which pt’s would u consider this in?
  2. Serology?
  3. monitor? (3)
  4. Prophylatic antiviral therapy with?
  5. Duration ?
A
  1. pt’s receiving exog immunosupp such as cancer, transplant, autoimmune
  2. HBsAg + or -, AND antiHBc +
  3. HBV DNA, HBsAg seroconversion (if previously neg), ALT/AST
  4. entecavir or tenofovir
  5. 6-12 months after discontinuation of anticancer therapy or immunosupp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Hep B prevention of transmission

  1. What should people who are HBsAg positive do?
A
  1. Have household or sex partners vaxxed, use barrier protection during sex if partner is not vaxxed, not share toothrbush or razors, not share injection equip, not share glucose testing stuff, cover open cuts and scratches, clean blood spills with bleach! Not donate blood, organs or sperm !
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HEP C : CLinical features

  1. Majority of pt’s have ?
  2. Chronic infection develops in ?
  3. Extraheptic manifestations? (4)
  4. Cirrhosis develops in ?
  5. Hepatocellular carcinoma (HCC risk)?
A
  1. no/mild sx’s
  2. 80%
  3. glomerulonephritis, mixed cryoglobulinemia , corneal ulcers, RA
  4. 20%
  5. 1-4% per year
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HEP C GOALS of therapy

  1. How to cure?
  2. What is SVR ? When do we want to see a negative HCV RNA?
  3. Improve ___
  4. Prevent progression to ___ , ___
  5. Prevent devel of ___ and ___
A
  1. eradicate the virus
  2. sustained viral response. 12 weeks after the end of therapy
  3. clinical sx’s
  4. cirrhosis, HCC
  5. end stage liver disease , complications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Guidance on HC tx?

  • TX reccc for ? except those with? who cannot be remediated by?
A
  1. all patients w/chornic HCV infection , except those w/short life expectancies who cant be remediated by treating HCV by transplantation or by other directed therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Focus on these oral regimens : State component classes and approved for which genotypes

  1. Sofosbuvir/Velpatasvir (EPCLUSA)
  2. Glecaprevir / Pibrentasvir (MAVYRET)
A
  1. Nucleotide polymerase inhib + NS5A inhib

-Genotypes 1-6

  1. Protease inhib + NS5A inhib

Genotypes 1-6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sofosbuvir/Velpatasvir (EPCLUZA)

  1. Class?
  2. Year approved?
  3. fda indicated for which genotypes?
  4. AE’s ? (2)
  5. Drug interactions?
A
  1. NS5B polymerase inhib /NS5A replication complex inhib
  2. 2016 June
  3. Genotypes 1-6
  4. Fatigue and HA
  5. Avoid strong inducers of PGP; avoid PPPI’s and other drugs that increase gastric pH
17
Q

Glecaprevir/Pibrentasvir (Mavyret)

  1. Class?
  2. year approved?
  3. Genotypes?
  4. AE’s
  5. Drug interactions
  6. CI?
A
  1. Protease inhibitor / NS5A inhib
  2. August of 2017
  3. 1-6
  4. Fatigue and headache
  5. rifampin, carbamazepine, SJW, HMGCOA reductase inibitors (statins)
  6. Child’s class C, rifampin, atazanavir
18
Q

HCV Tx algorithm for tx naive adults w/o cirrhosis

  1. Who is eligible?
  2. Who is not eligible?
  3. For pre-tx , what labs should u run?
A
  1. Adults/w chronic hep C (any genotype) who do NOT have cirrhosis and have NOT previously received hep c tx
  2. Pt’s who have any of the following
    - prior hep c tx
    - cirrhosis
    -HIV or HBsAg positive
    -current preg
    -known or suspected hepatocellular carcinoma
    -prior liver transplant
  3. Quantitative HCV RNA (HCV viral load)
    -HIV antigen/antibody test
    -HepB surface antigen
19
Q

HCV Recommended tx regimen for tx naive

Name the two regimens and dosing

A
  1. Glecaprevir 300 mg/ pibrentasvir 120 mg . Taken with food for a duration of 8 weeks
  2. Sofosbuvir 400 mg/velpatasvir 100 mg . for a duration of 12 weeks
20
Q

On tx monitoring

  1. What if a pt is taking diabetes meds?
  2. what if a pt is taking warfarin?
A
  1. they may experience potential symptomatic hypoglycemia . Monitor for hypoglycemia
  2. changes in anticoag status! Monitor pt INR for subtherapeutic anticoagulation
21
Q

Prior to starting tx, which score do u have to calculate and what value would u not initiate tx in?

A

U need to calculate FIB-4 score. if the FIB-4 score is >3.25, they have cirrhosis and u cannot start therapy

22
Q

DDI: Mavyret

  1. Digoxin , effect ? Monitor?
  2. Carbamazepine, Rifampin
  3. SJW?
  4. Statins

What about rosuvastatin , fluvastatin, and pitavastatin?

  1. Cyclosporine?
A
  1. INCR digoxin concs, monitor digoxin concs
  2. Decr conc of glecaprevir, pibrentasvir . Concomitant use not recc
  3. Decr mavyret concs, concomitant use not recc
  4. incr conc of ator, lova, simv, prav. Concomitant use with ator, lova, sim not recommended !
  • Decr prava dose by 50%
    -Rosuv dose should be less than or equal to 10 mg
    -use lowest dose possible of fluvatstain or pitava
  1. It increases the concentration of mavyret. NOT reccc with cyclosporine doses over 100 mg per day
23
Q

DDI : Epclusa

  1. Digoxin?
  2. Amiodarone?
  3. Carbam, rifampin, phenytoin, phenobarb?
  4. SJW?
  5. ACid reducers? what changes to dosing do u have to do?
  6. Statins?
  7. Topotecans
  8. Efavirenz
A
  1. Digoxin concentrations incr, need to monitor digoxin concs
  2. Amiodarone is CI bc it causes serious bradycardia
  3. Decr Epclusa concentrations. concomittant use is NOT recc
  4. DECR epclusa concs. Concomitant use NOT recc
  5. DECREASES VELPATASVIR.
  • Admin H2RAs 12 hrs apart from EPCLUSA (NTE famotidine 40 mg twice daily or equivalent)
    -omeprazole and other PPI’s are not recc ; if necessary take EPCLUSA 4 hrs before omeprazole 20 mg
  1. Incr atorvastatin and rosuvastatin concentrations. Dose of rosuv should be equal to or less than 10. MONITOR FOR SAMS
  2. Incr topotecan conc. dont use together
  3. decr velpatasvir –> dont use together
24
Q

HBV reactivation in pt’s receiving HCV DAA’s

  1. Possibly due to?
  2. October 2016 FDA issued boxed warning for all ?
  3. Need to ?
A
  1. loss of host immune response to HBV
  2. HCV DAA therapies
  3. check HepB serology PRIOR to starting HCV DAA therapy
    - HBsAg, anti HBc and anti-HBs
25
Q

HepC Prevention
1. There’s no __ no effective __

NON PHARM THERAPY

  1. __ and __ vax
  2. Discontinue ?
  3. Balanced __ and __
  4. Avoid __, and __
  5. Practice ___
  6. NO sharing of ___
  7. Cover ___
  8. Use ___
A
  1. vaccine, immunoglobulin
  2. hep a and hep b
  3. alcohol and tobacco
  4. balanced diet , exercise
  5. illict drugs, herbal drugs
  6. safe sex practices like condoms
  7. razors/toothbrushes
  8. open wounds
  9. needle exhcchange programs

Therapeutics (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions